|
1
|
Saleem F and Rizvi SW: New therapeutic
approaches in obesity and metabolic syndrome associated with
polycystic ovary syndrome. Cureus. 9:e18442017.PubMed/NCBI
|
|
2
|
Marchitto N, Sindona F, Fabrizio A, Mauti
M, Andreozzi S, Dalmaso S and Raimondi G: Effect of new
nutraceutical formulation with policosanol, berberine, red yeast
rice, cassia nomame, astaxantine and Q10 coenzyme in patients with
low-moderate dyslipidemia associated with intolerance to statins
and metabolic syndrome. Minerva Cardioangiol. 66:124–125.
2018.PubMed/NCBI
|
|
3
|
Liu Q, Zhu L, Cheng C, Hu YY and Feng Q:
Natural active compounds from plant food and chinese herbal
medicine for nonalcoholic fatty liver disease. Curr Pharm Des.
23:5136–5162. 2017.PubMed/NCBI
|
|
4
|
Dahlberg CJ, Ou JJ, Babish JG, Lamb JJ,
Eliason S, Brabazon H, Gao W, Kaadige MR and Tripp ML: A 13-week
low glycemic load diet and lifestyle modification program combining
low glycemic load protein shakes and targeted nutraceuticals
improved weight loss and cardio-metabolic risk factors. Can J
Physiol Pharmacol. 95:1414–1425. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sirtori CR, Pavanello C, Calabresi L and
Ruscica M: Nutraceutical approaches to metabolic syndrome. Ann Med.
49:678–697. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guarino G, Strollo F, Carbone L, Della
Corte T, Letizia M, Marino G and Gentile S: Bioimpedance analysis,
metabolic effects and safety of the association Berberis
aristata/Bilybum marianum: A 52-week double-blind,
placebo-controlled study in obese patients with type 2 diabetes. J
Biol Regul Homeost Agents. 31:495–502. 2017.PubMed/NCBI
|
|
7
|
Tabeshpour J, Imenshahidi M and
Hosseinzadeh H: A review of the effects of Berberis vulgaris and
its major component, berberine, in metabolic syndrome. Iran J Basic
Med Sci. 20:557–568. 2017.PubMed/NCBI
|
|
8
|
Ong M, Peng J, Jin X and Qu X: Chinese
herbal medicine for the optimal management of polycystic ovary
syndrome. Am J Chin Med. 45:405–422. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu YH, Lu JM, Wang SY, Li CL, Liu LS,
Zheng RP, Tian H, Wang XL, Yang LJ, Zhang YQ and Pan CY: Comparison
of the diagnostic criteria of metabolic syndrome by International
Diabetes Federation and that by Chinese Medical Association
Diabetes Branch. Zhonghua Yi Xue Za Zhi. 86:386–389. 2006.(In
Chinese). PubMed/NCBI
|
|
10
|
Zhao L, Cang Z, Sun H, Nie X, Wang N and
Lu Y: Berberine improves glucogenesis and lipid metabolism in
nonalcoholic fatty liver disease. BMC Endocr Disord. 17:132017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Choi YJ, Lee KY, Jung SH, Kim HS, Shim G,
Kim MG, Oh YK, Oh SH, Jun DW and Lee BH: Activation of AMPK by
berberine induces hepatic lipid accumulation by upregulation of
fatty acid translocase CD36 in mice. Toxicol Appl Pharmacol.
316:74–82. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chow YL, Sogame M and Sato F:
13-Methylberberine, a berberine analogue with stronger
anti-adipogenic effects on mouse 3T3-L1 cells. Sci Rep.
6:381292016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He Q, Mei D, Sha S, Fan S, Wang L and Dong
M: ERK-dependent mTOR pathway is involved in berberine-induced
autophagy in hepatic steatosis. J Mol Endocrinol. 57:251–260. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li M, Shu X, Xu H, Zhang C, Yang L, Zhang
L and Ji G: Integrative analysis of metabolome and gut microbiota
in diet-induced hyperlipidemic rats treated with berberine
compounds. J Transl Med. 14:2372016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Millán J, Cicero AF, Torres F and Anguera
A: Effects of a nutraceutical combination containing berberine
(BRB), policosanol, and red yeast rice (RYR), on lipid profile in
hypercholesterolemic patients: A meta-analysis of randomised
controlled trials. Clin Investig Arterioscler. 28:178–187.
2016.PubMed/NCBI
|
|
16
|
Martínez-Abundis E, Méndez-Del Villar M,
Pérez-Rubio KG, Zuñiga LY, Cortez-Navarrete M, Ramírez-Rodriguez A
and González-Ortiz M: Novel nutraceutic therapies for the treatment
of metabolic syndrome. World J Diabetes. 7:142–152. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Caliceti C, Franco P, Spinozzi S, Roda A
and Cicero AF: Berberine: New insights from pharmacological aspects
to clinical evidences in the management of metabolic disorders.
Curr Med Chem. 23:1460–1476. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patel S: Functional food red yeast rice
(RYR) for metabolic syndrome amelioration: A review on pros and
cons. World J Microbiol Biotechnol. 32:872016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Geng FH, Li GH, Zhang X, Zhang P, Dong MQ,
Zhao ZJ, Zhang Y, Dong L and Gao F: Berberine improves mesenteric
artery insulin sensitivity through up-regulating insulin
receptor-mediated signalling in diabetic rats. Br J Pharmacol.
173:1569–1579. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oikawa N, Nobushi Y, Wada T, Sonoda K,
Okazaki Y, Tsutsumi S, Park YK, Kurokawa M, Shimba S and Yasukawa
K: Inhibitory effects of compounds isolated from the dried branches
and leaves of murta (Myrceugenia euosma) on lipid
accumulation in 3T3-L1 cells. J Nat Med. 70:502–509. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cicero AF and Colletti A: Role of
phytochemicals in the management of metabolic syndrome.
Phytomedicine. 23:1134–1144. 2016. View Article : Google Scholar : PubMed/NCBI
|
